Cantor Fitzgerald Predicts RCKT FY2025 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Rocket Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the biotechnology company will post earnings of ($3.20) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $65.00 target price on the stock. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share.

A number of other equities analysts also recently weighed in on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $39.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Wedbush began coverage on shares of Rocket Pharmaceuticals in a research report on Monday, December 30th. They issued an "outperform" rating and a $32.00 price objective for the company. Leerink Partners decreased their price objective on Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 19th. Jefferies Financial Group began coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They issued a "buy" rating and a $29.00 target price for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $52.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $47.27.

Rocket Pharmaceuticals Price Performance

NASDAQ RCKT traded up $0.60 on Thursday, hitting $11.08. 1,281,089 shares of the company were exchanged, compared to its average volume of 1,644,654. Rocket Pharmaceuticals has a 1-year low of $10.07 and a 1-year high of $31.47. The firm has a 50 day moving average of $12.46 and a two-hundred day moving average of $16.92. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The company has a market cap of $1.01 billion, a P/E ratio of -4.03 and a beta of 1.01.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.07.

Institutional Investors Weigh In On Rocket Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Rocket Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 582 shares during the period. KBC Group NV boosted its holdings in shares of Rocket Pharmaceuticals by 159.6% in the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock valued at $69,000 after buying an additional 3,366 shares during the period. Values First Advisors Inc. bought a new stake in shares of Rocket Pharmaceuticals during the third quarter worth $108,000. SG Americas Securities LLC acquired a new stake in shares of Rocket Pharmaceuticals during the third quarter worth $113,000. Finally, XTX Topco Ltd bought a new stake in Rocket Pharmaceuticals in the 3rd quarter valued at $286,000. Institutional investors and hedge funds own 98.39% of the company's stock.

Insider Activity at Rocket Pharmaceuticals

In related news, CEO Gaurav Shah sold 11,091 shares of the firm's stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $13.05, for a total transaction of $144,737.55. Following the sale, the chief executive officer now owns 707,328 shares of the company's stock, valued at approximately $9,230,630.40. This trade represents a 1.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 13,490 shares of company stock worth $176,045. 28.50% of the stock is currently owned by company insiders.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.